Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families

NCT00393224 · clinicaltrials.gov ↗

TERMINATED

Status

952

Enrollment

NIH

Sponsor class

Stopped Determined not to be human subject reseach

Conditions

Nasopharyngeal Neoplasms

Sponsor

National Cancer Institute (NCI)